2552.HK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 16:08):

Stats
今日成交量	590 000
平均成交量	1.05M
市值	1.58B
EPS	HKD0 ( 2024-03-27 )
下一个收益日期	( HKD0 ) 2024-06-27
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-6.71
ATR14	HKD0.00700 (0.45%)

Hua Medicine 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Hua Medicine 财务报表

Annual	2023
营收:	HKD76.61M
毛利润:	HKD37.37M (48.78 %)
EPS:	HKD-0.220

FY	2023
营收:	HKD76.61M
毛利润:	HKD37.37M (48.78 %)
EPS:	HKD-0.220

FY	2022
营收:	HKD17.60M
毛利润:	HKD7.69M (43.69 %)
EPS:	HKD-0.210

FY	2021
营收:	HKD0.00
毛利润:	HKD0.00 (0.00 %)
EPS:	HKD-0.340

Financial Reports:

No articles found.

Hua Medicine

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.